anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Highly active antiretroviral therapy (HAART) has been able to improve the immune system function and survival of human immunodeficiency virus (HIV) patients. However, Patients coinfected with HIV and hepatitis B virus (HBV) are more likely to develop end-stage liver disease (ESLD) than those infected with HBV alone. Consequently, liver transplantation is often required for these patients. This study evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-HBV coinfected patients in China.
METHODS: We conducted a retrospective analysis on all HIV-HBV coinfected patients that underwent OLT from April 1, 2019 to December 31, 2021 and their outcomes were compared to all HBV monoinfected patients undergoing OLT during the same period. Patient outcomes were determined, including cumulative survival, viral load, CD4 T-cell count and postoperative complications.
RESULTS: The median follow-up of HIV recipients was 36 months after OLT (interquartile range 12-39 months). Almost all patients had stable CD4 T-cell count (> 200 copies/ul), undetectable HBV DNA levels, and undetectable HIV RNA load during follow-up. The 1-, 2-, and 3-year posttransplant survival rates were 85.7% for the HIV group (unchanged from 1 to 3 years) versus 82.2%, 81.2%, and 78.8% for the non-HIV group. Cumulative survival among HIV-HBV coinfected recipients was not significantly different from the HBV monoinfected recipients (log-rank test P = 0.692). The percentage of deaths attributed to infection was comparable between the HIV and non-HIV groups (14.3% vs. 9.32%, P = 0.665). Post OLT, there was no significant difference in acute rejection, cytomegalovirus infection, bacteremia, pulmonary infection, acute kidney injury, de novo tumor and vascular and biliary complications.
CONCLUSIONS: Liver transplantation in patients with HIV-HBV coinfection yields excellent outcomes in terms of intermediate- or long-term survival rate and low incidence of postoperative complications in China. These findings suggest that OLT is safe and feasible for HIV-HBV coinfected patients with ESLD.
TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300067631), registered 11 January 2023.
Carcinogenicity assessment has been conducted in mice, rats and p53 (+/-) heterozygous mice. A slight, but statistically significant, increase in two common murine tumors, pulmonary and hepatic, was observed in a mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg (90 mg/m2 or 0.5 times the maximum daily human dosage of 185 mg/m2) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans.

No treatment-related tumors were noted in a rat carcinogenicity study (dosing orally up to 30 mg/kg, 180 mg/m2, or equivalent to the maximum daily human dosage) or in a second study where rats were treated with up to 75 mg/kg/day for males and 100 mg/kg/day for females (approximately 2.4 and 3.2-fold MDHD, respectively) for two years. However, the excessive decrease in body weight gain observed in the rat study might have reduced their sensitivity to any potential carcinogenic effect of the drug.

No carcinogenic effect of tramadol was observed in p53(+/–)-heterozygous mice at oral doses up to 150 mg/kg/day (approximately 2.4-fold maximum daily human dose [MDHD] of 300 mg/day for a 60 kg adult based on body surface conversion) for 26 weeks.

Tramadol was not mutagenic in the following assays: a bacterial reverse mutation assay using Salmonella and E. coli, a mouse lymphoma assay (in the absence of metabolic activation), chromosomal aberration test in Chinese hamsters, a bone marrow micronucleus test in mice and Chinese hamsters, and a dominant lethal mutation test in mice. Mutagenic results occurred in the presence of metabolic activation in the mouse lymphoma assay and micronucleus test in rats. Overall, the weight of evidence from these tests indicates that tramadol does not pose a genotoxic risk to humans.

No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg/day in male and female rats (1.6-fold the MDHD).
Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
Participants who are randomized to the experimental group (EXP arm) will receive a single-shot axillary-approach brachial plexus block with 1.5mg/kg (up to 50mg total) bupivacaine 0.25% at the Kingston Health Sciences Centre Chronic Pain Clinic (KHSC-CPC). Prior to treatment, a blinded third party will perform a baseline physical exam. Under the brachial plexus block, the physiotherapist will provide standard of care, including manual therapy. The patient will then complete a 6-week physiotherapy program, including GMI. Following the 6 week program, a blind observer will repeat the physical exam.
Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy. E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
Healing of endoscopically verified erosion and symptomatic improvement were studied in a U.S. and an international double-blind trials. Healing was defined as complete resolution of all erosions visible with endoscopy. The U.S. trial comparing orally administered famotidine 40 mg twice daily to placebo and orally administered famotidine 20 mg twice daily showed a significantly greater percentage of healing of erosive esophagitis for famotidine 40 mg twice daily at Weeks 6 and 12 (Table 7). 

As compared to placebo, patients in the U.S. trial who received famotidine had faster relief of daytime and nighttime heartburn, and a greater percentage of famotidine-treated patients experienced complete relief of nighttime heartburn. These differences were statistically significant. 

In the international trial, when orally administered famotidine 40 mg twice daily was compared to orally administered ranitidine 150 mg twice daily, a statistically significantly greater percentage of healing of erosive esophagitis was observed with famotidine 40 mg twice daily at Week 12 (Table 8). There was, however, no significant difference in symptom relief among treatment groups.
The present invention discloses a medicine composition for treating ischemic femoral head necrosis and a preparing method of a medicine composition for treating ischemic femoral head necrosis. The medicine composition for treating ischemic femoral head necrosis is composed of the following raw materials: red sage roots, Chinese angelica roots, psoraleae, leeches, eupolyphaga, astragalus roots, tougu grass, pyritum, eucommia barks, notoginseng and cinnamon. Ethanol is extracted from the red sage roots, the Chinese angelica roots, the psoraleae, the leeches and the eupolyphaga; water is extracted from the astragalus roots, the tougu grass, the pyritum and the eucommia barks; the red sage roots, the Chinese angelica roots, the psoraleae, the leeches, the eupolyphaga, the astragalus roots, the tougu grass, the pyritum and the eucommia barks are mixed with the pulverized notoginseng and the pulverized cinnamon, atomized, dried and filled in capsules to obtain the patent medicine. The medicine composition has remarkable effect on treating the ischemic femoral head necrosis, and the total effective rate is 88%. The medicine composition can obviously improve cardinal symptom physical signs, such as coxodynia, lameness, functional disorder, etc., of the ischemic femoral head necrosis, and the imaging performance of the ischemic femoral head necrosis is also improved. The medicine composition for treating ischemic femoral head necrosis has the advantages of advanced preparing process, small medicine capsule dosage, convenient administration and no chemical sweetening agent. The medicine composition for treating ischemic femoral head necrosis is suitable for any patient without any toxic side effect found.
The investigators planned to recruit 10 volunteers with a BMI between 30 and 35. Half male, half female. There are no age restrictions. The volunteers in this group were obese patients. The investigators will look at the differences in body composition measured by different methods for each individual in this group.
All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
The invention belongs to the technical field of biology, and particularly relates to a tandem dominant epitope recombinant erysipelothrix rhusiopathiae surface protective antigen A (SpaA) and application thereof. The amino acid sequence of the recombinant erysipelothrix rhusiopathiae surface protection antigen A with the tandem dominant epitope is shown as SEQ ID No.1, and the nucleotide sequence for coding the protein is shown as SEQ ID No.2. The invention further constructs an expression vector containing the nucleotide sequence, and the sequence is shown as SEQ ID No. 3. Transforming colibacillus to obtain recombinant expression strain. The recombinant erysipelothrix rhusiopathiae surface protection antigen A with the tandem dominant epitope is uniformly mixed with an adjuvant, and can induce an organism to generate an immune response after a mouse is immunized, so that a 100% immune protection effect for resisting 1000MLD virulent attack can be provided for an attacking mouse; after the pig is immunized, 67% of immune protection effect for resisting 2MLD virulent attack can be provided for the attacking pig, and 100% of immune protection effect for resisting 1MLD virulent attack can be provided for the attacking pig.
Metastatic breast cancer (MBC) is a complex disease with variability in disease subtype, length of survival, treatment selection, symptom burden, and, ultimately, end-of-life (EOL) care. Influencing factors that contribute to the complexity of this disease are socioeconomic factors, provider differences, and patient and family preferences. Because of this variability, it is challenging for health care providers to know when treatments are no longer helpful but contribute to a poor quality of end-of-life care and a poor death experience for both patients and their families. Determining the unique point, based on their own values and goals, at which patients and their family members feel that MBC treatment becomes unhelpful and unwanted, is difficult to ascertain. Of the 25 individuals who participated in the Quality of Death and Dying survey, 16 individuals participated in an interview to provide a reflection of the patient's EOL experience and its congruence with their wishes. Four major categories emerged as primary priorities essential to high quality end-of-life care, that is, resilience, communication, support, and knowledge. Without tailored and precise care, patients with MBC will continue to receive prolonged, inappropriate, and costly treatment, resulting in a potentially unacceptable poor-quality EOL and death experience.
INTRODUCTION: the risk management system is useful to identify, analyze, and reduce the risk occurrence of adverse events (AEs) in health services. This system suggests useful improvements to patients and to the whole institution and also contributes to the acquisition of a collective and organizational safety culture. This study presented a state of the art of the management of AEs identified in different services of a regional hospital in the north of Morocco.
METHODS: this is a retrospective cross-sectional exploratory study carried out from 2017 to 2019 using observations and semi-structured interviews, which were recorded, re-transcribed, and analyzed. Data was also collected from audit reports, results of investigations of the nosocomial infection control committee and the risk management commission, AEs declaration sheets, and meetings reports.
RESULTS: a number of 83 AEs were recorded, 10 of which were urgent. The reported events were related to care, infection risk, the drugs circuit, and medico-technical events. Two hundred cases of nosocomial infections were also recorded, of which 75 occurred in the intensive care unit and 35 in the maternity service. Surgical site infections were the most frequently reported complication. Adverse events were related to organizational failure, equipment problems, and errors related to professional practices.
CONCLUSION: our findings may guide the improvement of the event management system in order to reduce the occurrence of future incidents. Thus, improving the risk management system requires setting up training strategies for staff on the importance of this system and its mode of operation.
Topical compsn. comprises a constituent (I) that stimulates the circulation in the arteries leading to the muscles of the skin, and a constituent (II) that stimulates the circulation in the capillaries adjacent to cutaneous cells. More specifically (I) is pref. a tincture of Cayenne pepper. (II) is a tincture of Vaccinium myrtillus, Gingko biloba, or thyme, or their mixtures. The compsns. may contain an aromatic essential oil, such as hyssop, sage, geranium, or oregano oils. The compsn. may be formulation as a liq. or gel using conventional vehicles such as marigold cream, lanolin oil, or their mixtures. USE - The compsn. rejuvenates the texture of the skin. In an example, a topical compsn. was prepd. from 2ml tincture of Cayenne pepper, as supplied for homeopathic purposes, 2ml of tincture of Vaccinium myrtilis, and 2ml tincture of thyme.
PURPOSE: Idiopathic sudden sensorineural hearing loss (ISSHL) can cause acute damage not only to the auditory function, but also to the vestibular function in addition to damage to the hearing function. The aim of this study was to perform vestibular assessment using caloric test and video head impulse test in patients with idiopathic sudden sensorineural hearing loss. In addition, to evaluate the relationship of dizziness with vestibular tests and post-treatment responses of vestibular tests.
METHODS: This is an observational, longitudinal and prospective study, including patients diagnosed with idiopathic sudden sensorineural hearing. Patients were divided into two groups according to the presence of vestibular complaints at presentation: Group 1: Patients with vestibular complaints, Group 2: Patients without vestibular complaints. All subjects underwent pure tone audiometry (PTA) testing, cold caloric test and video head impulse test (vHIT) during their admission and on the 10th day, 3rd month, and 1st year of their follow-up outpatient clinic controls. A unilateral weakness (UW) in the caloric test response was quantified according to the Jongkees formula.
RESULTS: A positive and significant relationship was found between the degree of hearing loss according to the ASHA criteria pre-treatment and the level of improvement created according to Siegel criteria at the 10th day, 3rd month, 1st year after treatment (respectively p = 0.001, p = 0.001, p < 0.001). When both short-term and long-term results were evaluated after treatment, a positive improvement in the degree of hearing loss was observed. A statistically significant difference was observed between Groups 1 and 2 when the pre-treatment, at 10 days, 3 months and 1 year after treatment the caloric test UW value was compared (respectively p = 0.020, p = 0.004, p = 0.004, p = 0.004). A statistically significant difference was observed between Groups 1 and 2 when the pre-treatment, at 10 days, 3 months and 1 year after treatment vHIT lateral canal VOR value was compared (respectively p = 0.000, p = 0.001, p = 0.000, p = 0.004). When both short-term and long-term results were evaluated after treatment, a positive improvement was observed in both caloric test results and lateral vHIT VOR values. Pre-treatment, post-treatment 10th day, 3rd month, 1st year vHIT anterior and posterior canal VOR values were found to be VOR˃0.8 in all patients. No difference was observed in anterior and posterior canal VOR values.
CONCLUSION: Vertigo in patients with ISSHL "as objectively confirmed through caloric testing and vHIT" can be considered a sign of severe cochlear damage. Our study demonstrated a significantly increased risk of vestibular affect in patients with ISSHL, especially in the presence of vertigo. Thus, we conclude that the focus in ISSHL should not only be on the cochlea but also on the vestibular system.
The invention relates to Dai nationality medicine for treating rheumatism, which is powder or capsules formed by mixing the following raw materials in parts by weight, or tablets or capsules obtained in a boiling way from mixture: 0.1 to 0.5 part of erythrina indica lam, 1 to 2 parts of sargentgloryvine stem, 0.5 to 1.5 parts of gynostemma pentaphylla, 1 to 2 parts of root of panax notoginseng, 0.2 to 1 part of Eriosema himalaicum Ohashi, 0.2 to 1 part of Maytenus hookeri, 0.1 to 0.9 part of Paris polyphylla, 1 to 2 parts of the root of red-rooted salvia, 1 to 2 parts of spicy root, and 4 to 8 parts of kusnezoff monkshood root, wherein the fineness of the powder is generally not less than 120 meshes, and the powder can be directly taken by boiling water. The Dai nationality medicine is characterized by having fast effect to rheumatic diseases, such as stubborn rheumatoid arthritis. When the medicine is continuously taken for a week, swelling fades away, and pain sharply reduces. The effective rate of the medicine can reach 95%, and the recovery rate can reach 30%. For tumours, such as myoma of uterus and on the like, the effective rate of the medicine can reach 85%, and the recovery rate can reach 30%. In addition, the medicine also has obvious curative effect to the diseases, such as lumbar hyperosteogeny, knee bone hyperplasia, general waist ache, scapulohumeral periarthritis, sciatica and on the like.
As the representative item of environmental chemical carcinogen, MNNG was closely associated with the onset of Gastric cancer (GC), while the underlying mechanisms remain largely unknown. Here, we comprehensively analyzed the potential clinical significance of METTL3 in multiple GC patient cohorts. Additionally, we demonstrated that long-term exposure to MNNG elevated METTL3 and EMT marker expression by in vitro and in vivo models. Furthermore, the depletion of METTL3 impacted the proliferation, migration, invasion, and tumorigenesis of MNNG malignant transformation cells and GC cells. By me-RIP sequencing, we identified a panel of vital miRNAs potentially regulated by METTL3 that aberrantly expressed in MNNG-induced GC cells. Mechanistically, we showed that METTL3 meditated miR-1184/TRPM2 axis by regulating the process of miRNA-118. Our results provide novel insights into critical epigenetic molecular events vital to MNNG-induced gastric carcinogenesis. These findings suggest the potential therapeutic targets of METTL3 for GC treatment.
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
Single case studies of extraordinary disease resilience may provide therapeutic insight into conditions for which no definitive treatments exist. An otherwise healthy 35-year-old man (patient-R) with the canonical pathogenic ACVR1R206H variant and the classic congenital great toe malformation of fibrodysplasia ossificans progressiva (FOP) had extreme paucity of post-natal heterotopic ossification (HO) and nearly normal mobility. We hypothesized that patient-R lacked a sufficient post-natal inflammatory trigger for HO. A plasma biomarker survey revealed a reduction in total matrix metalloproteinase-9 (MMP-9) compared to healthy controls and individuals with quiescent FOP. Whole exome sequencing identified compound heterozygous variants in MMP-9 (c.59C > T, p.A20V and c.493G > A, p.D165N). Structural analysis of the D165N variant predicted both decreased MMP-9 secretion and activity that were confirmed by enzyme-linked immunosorbent assay and gelatin zymography. Further, human proinflammatory M1-like macrophages expressing either MMP-9 variant produced significantly less Activin A, an obligate ligand for HO in FOP, compared to wildtype controls. Importantly, MMP-9 inhibition by genetic, biologic, or pharmacologic means in multiple FOP mouse models abrogated trauma-induced HO, sequestered Activin A in the extracellular matrix (ECM), and induced regeneration of injured skeletal muscle. Our data suggest that MMP-9 is a druggable node linking inflammation to HO, orchestrates an existential role in the pathogenesis of FOP, and illustrates that a single patient's clinical phenotype can reveal critical molecular mechanisms of disease that unveil novel treatment strategies.
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and / or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models. The present invention relates to IDR peptides comprising the amino acid sequence of SEQ ID NO. 91 or 92 or a pharmaceutical salt, ester, or amide thereof
Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
The invention discloses aspergillus fumigatus AF‑hypo Genes and application thereof, which belong to the field of genetic engineering. The technical key points of the invention are as follows: aspergillus fumigatus AF‑hypo Gene, aspergillus fumigatus AF‑hypo The nucleotide sequence of the gene is shown as SEQ ID NO. 1. Aspergillus fumigatus of the invention AF‑   hypo The gene can be used as a design target of a targeted drug or applied to screening aspergillosisIs used for treating the disease. AF‑hypo The gene deletion results in an increased sensitivity of aspergillus fumigatus to voriconazole. Clinically if it is to be AF‑hypo The use amount of voriconazole can be reduced and better therapeutic effect can be achieved after the expression quantity of the gene is regulated downwards. The composition has extremely high application value for treating clinical deep aspergillus fumigatus infection, in particular to drug-resistant aspergillus infection.